PE20190440A1 - Anticuerpos a la alfa-sinucleina y usos de los mismos - Google Patents

Anticuerpos a la alfa-sinucleina y usos de los mismos

Info

Publication number
PE20190440A1
PE20190440A1 PE2018003155A PE2018003155A PE20190440A1 PE 20190440 A1 PE20190440 A1 PE 20190440A1 PE 2018003155 A PE2018003155 A PE 2018003155A PE 2018003155 A PE2018003155 A PE 2018003155A PE 20190440 A1 PE20190440 A1 PE 20190440A1
Authority
PE
Peru
Prior art keywords
antibodies
antibody
comprised
treatment
synuclein
Prior art date
Application number
PE2018003155A
Other languages
English (en)
Spanish (es)
Inventor
Michael Perkinton
Darren Schofield
Lorraine Irving
George Thom
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of PE20190440A1 publication Critical patent/PE20190440A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
PE2018003155A 2016-06-02 2017-06-01 Anticuerpos a la alfa-sinucleina y usos de los mismos PE20190440A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662344746P 2016-06-02 2016-06-02

Publications (1)

Publication Number Publication Date
PE20190440A1 true PE20190440A1 (es) 2019-03-27

Family

ID=59021492

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018003155A PE20190440A1 (es) 2016-06-02 2017-06-01 Anticuerpos a la alfa-sinucleina y usos de los mismos
PE2023002924A PE20250392A1 (es) 2016-06-02 2017-06-01 Anticuerpos a la alfa-sinucleina y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2023002924A PE20250392A1 (es) 2016-06-02 2017-06-01 Anticuerpos a la alfa-sinucleina y usos de los mismos

Country Status (38)

Country Link
US (5) US10160800B2 (OSRAM)
EP (2) EP4000632A1 (OSRAM)
JP (3) JP7078552B2 (OSRAM)
KR (1) KR102499438B1 (OSRAM)
CN (2) CN109475616B (OSRAM)
AR (1) AR108663A1 (OSRAM)
AU (2) AU2017272804B2 (OSRAM)
BR (1) BR112018074978A2 (OSRAM)
CA (1) CA3025987A1 (OSRAM)
CL (1) CL2018003438A1 (OSRAM)
CO (1) CO2018014010A2 (OSRAM)
CY (1) CY1124896T1 (OSRAM)
DK (1) DK3463435T3 (OSRAM)
EA (2) EA038358B1 (OSRAM)
EC (1) ECSP18096095A (OSRAM)
ES (1) ES2903402T3 (OSRAM)
GE (1) GEP20217253B (OSRAM)
HR (1) HRP20211935T1 (OSRAM)
HU (1) HUE057214T2 (OSRAM)
IL (1) IL263243A (OSRAM)
LT (1) LT3463435T (OSRAM)
MA (1) MA45125B1 (OSRAM)
MD (1) MD3463435T2 (OSRAM)
MX (1) MX393740B (OSRAM)
MY (1) MY188183A (OSRAM)
NZ (1) NZ748616A (OSRAM)
PE (2) PE20190440A1 (OSRAM)
PH (1) PH12018502538A1 (OSRAM)
PL (1) PL3463435T3 (OSRAM)
PT (1) PT3463435T (OSRAM)
RS (1) RS62682B1 (OSRAM)
SG (1) SG11201810420YA (OSRAM)
SI (1) SI3463435T1 (OSRAM)
SM (1) SMT202200008T1 (OSRAM)
TW (2) TW202309093A (OSRAM)
UA (1) UA124733C2 (OSRAM)
WO (1) WO2017207739A1 (OSRAM)
ZA (1) ZA201808582B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JP7217229B2 (ja) 2016-11-15 2023-02-02 ハー・ルンドベック・アクチエゼルスカベット シヌクレイノパチーの治療のための薬剤、使用および方法
ES3008133T3 (en) 2016-12-16 2025-03-21 H Lundbeck As Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
CA3150726A1 (en) 2019-09-20 2021-03-25 Jing Guo Anti-alpha-synuclein antibodies and methods of use thereof
KR102239512B1 (ko) * 2020-09-10 2021-04-12 서울대학교산학협력단 다중기능성 마이크로캡슐 조성물 및 그 제조방법
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CN113912716B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 针对α-突触核蛋白抗原的抗体及其应用
AU2023417097A1 (en) 2022-12-29 2025-08-14 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5198704B2 (ja) 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
HUE035044T2 (en) 2003-05-19 2018-05-02 Prothena Biosciences Ltd Truncated fragments of alpha-synuclein in Lewy-body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
CA2623841C (en) 2005-09-27 2019-03-12 National Research Council Of Canada Methods of identifying agents capable of tmem30a mediated transmigration across the blood brain barrier (bbb)
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4934074B2 (ja) 2007-03-07 2012-05-16 株式会社アルファ スイッチ固定構造
LT2282758T (lt) 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
PT2370466E (pt) 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
JP4654348B1 (ja) 2010-02-23 2011-03-16 多摩川精機株式会社 検出装置用巻線の正弦波巻線方法
RU2555526C2 (ru) * 2010-02-26 2015-07-10 Байоарктик Ньюросайенс Аб Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
AU2012272790B2 (en) 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
EP3378535B1 (en) 2011-10-28 2023-01-04 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
PL3071597T3 (pl) * 2013-11-21 2020-11-30 F.Hoffmann-La Roche Ag Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania
HRP20210888T4 (hr) 2014-11-10 2024-12-06 Medimmune Limited Vezujuće molekule specifične za cd73 i njihova upotreba

Also Published As

Publication number Publication date
SI3463435T1 (sl) 2022-02-28
PL3463435T3 (pl) 2022-02-14
MY188183A (en) 2021-11-24
KR20190013923A (ko) 2019-02-11
AU2017272804B2 (en) 2023-11-23
AU2024200601A1 (en) 2024-04-18
PT3463435T (pt) 2021-11-22
NZ748616A (en) 2025-08-29
MX393740B (es) 2025-03-24
EA201892548A1 (ru) 2019-06-28
WO2017207739A1 (en) 2017-12-07
IL263243A (en) 2018-12-31
TWI765890B (zh) 2022-06-01
US10889639B2 (en) 2021-01-12
JP7078552B2 (ja) 2022-05-31
MA45125B1 (fr) 2021-11-30
CN109475616A (zh) 2019-03-15
CA3025987A1 (en) 2017-12-07
CN116120445A (zh) 2023-05-16
PH12018502538A1 (en) 2019-04-08
AU2017272804A1 (en) 2018-12-13
US20230331830A1 (en) 2023-10-19
CN109475616B (zh) 2022-10-18
LT3463435T (lt) 2021-12-27
CO2018014010A2 (es) 2019-01-18
EP4000632A1 (en) 2022-05-25
PE20250392A1 (es) 2025-02-11
ES2903402T3 (es) 2022-04-01
CY1124896T1 (el) 2023-01-05
JP2022110117A (ja) 2022-07-28
ECSP18096095A (es) 2019-01-31
US20190276522A1 (en) 2019-09-12
US20250263477A1 (en) 2025-08-21
JP2019527194A (ja) 2019-09-26
US10160800B2 (en) 2018-12-25
HRP20211935T1 (hr) 2022-03-18
US11560424B2 (en) 2023-01-24
SMT202200008T1 (it) 2022-03-21
UA124733C2 (uk) 2021-11-10
RS62682B1 (sr) 2021-12-31
US20180002411A1 (en) 2018-01-04
TW202309093A (zh) 2023-03-01
CL2018003438A1 (es) 2019-03-22
MA45125A (fr) 2021-06-02
MD3463435T2 (ro) 2022-03-31
EP3463435A1 (en) 2019-04-10
EA038358B1 (ru) 2021-08-13
GEP20217253B (en) 2021-05-13
KR102499438B1 (ko) 2023-02-14
MX2018014456A (es) 2019-08-12
TW201802119A (zh) 2018-01-16
SG11201810420YA (en) 2018-12-28
EP3463435B1 (en) 2021-10-13
US20210179698A1 (en) 2021-06-17
HUE057214T2 (hu) 2022-04-28
AR108663A1 (es) 2018-09-12
JP2024123247A (ja) 2024-09-10
DK3463435T3 (da) 2021-11-22
ZA201808582B (en) 2021-08-25
BR112018074978A2 (pt) 2019-03-12
EA202191380A1 (ru) 2021-08-26

Similar Documents

Publication Publication Date Title
PE20190440A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
Luo et al. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies
EA201890169A1 (ru) Тау-связывающие антитела
AR115389A1 (es) Anticuerpo antagonista de cd73
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
CL2013001468A1 (es) Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
EA202090227A1 (ru) Анти-lag-3 антитело, обладающее повышенной стабильностью
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
BR112015029953A2 (pt) anticorpos anti-tweakr e seus usos
EA202091710A1 (ru) Антитела против cd73 и способы их применения
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
AR092818A1 (es) Anticuerpo tau humanizado
AR085198A1 (es) Composicion farmaceutica
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
PE20160993A1 (es) Nuevos anticuerpos anti-dpep3 y metodos de uso
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX371442B (es) VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
BR112021023048A2 (pt) Moléculas de ligação a cd19 e usos das mesmas
CR20170138A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer
PE20180481A1 (es) Anticuerpos de union a tau
MX2018014016A (es) Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ